MAPT and Alzheimer disease: However, the recent failure in clinical phase III of semagacestat [37], γ-secretase inhibitor, as well as the clinical phases discontinuation of tideglusib [38], a GSK-3 inhibitor targeting tau protein, clearly show that the soundest hypotheses for AD have not yet provided any drug for AD patients cure.